Literature DB >> 8314473

Initial results with recombinant interferon alfa-2b in patients with chronic hepatitis C: the United States experience.

G L Davis1.   

Abstract

Early experience with recombinant interferon alfa-2b in chronic hepatitis C (HCV) has shown that normalisation of serum alanine aminotransferase activities and reduction in hepatic inflammation can be achieved in about 40% of patients. This occurs with loss of viral replication as measured by polymerase chain reaction for HCV-RNA. Further studies are needed to identify patients most likely to respond to treatment and to investigate the issues of non-response and relapse when treatment is stopped. Alternative interferon treatment regimens, as well as other drugs and combinations of agents, need to be investigated.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8314473      PMCID： PMC1374029          DOI： 10.1136/gut.34.2_suppl.s109

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  12 in total

1.  Expression of the novel extracellular matrix component tenascin in normal and diseased human liver. An immunohistochemical study.

Authors:  P Van Eyken; R Sciot; V J Desmet
Journal:  J Hepatol       Date:  1990-07       Impact factor: 25.083

2.  Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.

Authors:  J H Hoofnagle; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; M Peters; J G Waggoner; Y Park; E A Jones
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

3.  Acute unidentified hepatitis in a hypogammaglobulinaemic patient on intravenous gammaglobulin successfully treated with interferon.

Authors:  D Lockner; G Bratt; A Lindborg; E Törnebohm
Journal:  Acta Med Scand       Date:  1987

4.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France.

Authors:  P Marcellin; N Boyer; E Giostra; C Degott; A M Courouce; F Degos; H Coppere; P Cales; P Couzigou; J P Benhamou
Journal:  Hepatology       Date:  1991-03       Impact factor: 17.425

7.  Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C.

Authors:  M Shindo; A M Di Bisceglie; L Cheung; J W Shih; K Cristiano; S M Feinstone; J H Hoofnagle
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

8.  Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis.

Authors:  K Kiyosawa; Y Akahane; A Nagata; S Furuta
Journal:  Am J Gastroenterol       Date:  1984-10       Impact factor: 10.864

9.  Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy.

Authors:  A Castilla; J Prieto; N Fausto
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

10.  Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon.

Authors:  M Shindo; A M Di Bisceglie; J H Hoofnagle
Journal:  Hepatology       Date:  1992-06       Impact factor: 17.425
View more
  2 in total

1.  Analysis of biochemical and virological efficacy of human lymphoblastoid interferon (IFN) in patients with compensated type C liver cirrhosis: comparative study between increase in individual IFN dose and prolonging of treatment period, using a multicenter randomized controlled trial.

Authors:  H Shinzawa; Y Yoshida; O Masamune; T Toyota; T Takahashi; R Kasukawa; T Sudo; K Ishikawa; M Komatsu; M Ishii; T Takagi; S Hisamichi; S Sato; H Ichida
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

2.  The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha.

Authors:  D Palmović; I Kurelac; J Crnjaković-Palmović
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.